Skip to main content
Clinical Trials/NCT01828905
NCT01828905
Completed
N/A

A Prospective, Multicenter, Randomized Study Investigating the Use of CERAMENT™|BONE VOID FILLER as Bone Graft Substitute in Tibia Plateau Fractures

Johannes Gutenberg University Mainz16 sites in 1 country137 target enrollmentApril 2013

Overview

Phase
N/A
Intervention
Not specified
Conditions
AO 41-B2 and AO 41-B3 Tibia Fractures
Sponsor
Johannes Gutenberg University Mainz
Enrollment
137
Locations
16
Primary Endpoint
SF-12 Physical Component Summary (PCS) at week 26
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The aim of the study is to compare fracture healing, quality of life, pain, and cost of care of the use of CERAMENT™|BONE VOID FILLER as bone graft substitute to the use of autologous cancellous bone graft (iliac crest) in the treatment of patients with tibia fractures treated by internal fixation and void reconstruction.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
December 31, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Johannes Gutenberg University Mainz
Responsible Party
Principal Investigator
Principal Investigator

Univ.-Prof. Pol M. Rommens

Head of Department of Trauma Surgery, Director of the Center for Musculoskeletal Surgery

Johannes Gutenberg University Mainz

Eligibility Criteria

Inclusion Criteria

  • patients with traumatic, closed, depression fracture of the proximal tibia (limited to AO type B2 \& B3)
  • solitary trauma
  • candidate for bone grafting
  • patients between the age of 18 and 65 years
  • written informed consent obtained before any study-related activities
  • patients with communicative ability to understand the procedure and participate in the study and comply with the follow up program

Exclusion Criteria

  • patients with multiple injuries
  • polytrauma patients
  • compartment syndrome
  • previous iliac crest bone graft harvesting
  • local infection at the site of implantation
  • chronic pain disease
  • malignancy
  • rheumatoid arthritis
  • chronic cortisone intake
  • X-ray diagnostics not available, fracture cannot be classified

Outcomes

Primary Outcomes

SF-12 Physical Component Summary (PCS) at week 26

Time Frame: 26 weeks

Global pain VAS score at week 26

Time Frame: 26 weeks

Secondary Outcomes

  • SF-12 PCS and MCS at visit 5(6 weeks)
  • Utilisation of costs of care related resources(26 weeks)
  • SF-12 PCS and MCS at visit 4(1 week)
  • Bone healing(1, 6, 12 and 26 weeks)
  • SF-12 PCS and MCS at visit 6(12 weeks)
  • SF-12 PCS and MCS at visit 7(26 weeks)

Study Sites (16)

Loading locations...

Similar Trials